New ovarian cancer treatment with chemo plus maintenance medicines
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed Stage III or Stage IV ovarian, fallopian tube, or primary peritoneal cancer confirmed by pathology
- Your doctors plan to treat you with carboplatin + paclitaxel chemo before surgery (neoadjuvant chemo) with planned interval debulking
- Your tumor marker blood test CA-125 and CEA ratio is at least 25; if it’s lower, extra testing must show no other cancer is causing it
- You are female, age 18 or older, and able to complete study visits (good function score 0 or 1)
- You are not pregnant or breastfeeding, and you can follow birth-control rules during treatment and for a set time after your last doses
- Your blood counts and organ tests (kidney, liver, blood clotting) meet required minimums
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
This Phase 3 trial studies a three-step “extra” chemotherapy plan after surgery for people with certain advanced ovarian, fallopian-tube, or primary peritoneal cancers. The goal is to improve outcomes by lowering the chance the cancer comes back.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.